Latest Breaking News On - Houston methodist debakey heart vascular center - Page 2 : comparemela.com

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
Belgrade
Serbia-general
Toronto
Ontario
Canada
Ihren
Rheinland-pfalz
Germany
Serbia
American

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Toronto
Ontario
Canada
Belgrade
Serbia-general
Serbia
American
Andrew-hamer
Trevor-burns
Scientific-programme

Low-Risk TAVR Studies: Divergent Long-Term Results

Different results from long-term follow-up of the PARTNER-3 and Evolut trials evaluating TAVR vs surgery in low-surgical-risk patients are leading to some interesting discussions.

San-francisco
California
United-states
Corevalve-evolut
Michael-reardon
Edwards-lifesciences
Coll-cardiol
York-heart-association
Medtronic
Presbyterian-columbia-university-irving-medical-center
Houston-methodist-debakey-heart-vascular-center
Transcatheter-cardiovascular-therapeutics

Low-Risk TAVR Converging or Diverging With Surgical Outcomes, Depending on the Valve

Intermediate-term reports from PARTNER 3 and Evolut Low Risk trials

Boston
Massachusetts
United-states
New-york
Coll-cardiol
Nicole-lou
Bernard-prendergast
Michael-reardon
Pinak-shah
Kendra-grubb
Journal-of-the-american-college-cardiology
Emory-university-in-atlanta

Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)

While Cardiol Therapeutics stock may have given back some of its gains to profit-taking, investors holding since the new year have little to complain about. After all, since the turn to 2023, CRDL.

Monterrey
Nuevo-leóx
Mexico
United-states
Ottawa
Ontario
Canada
Americans
Cienciae-humanismo
University-of-ottawa-heart-institute
Houston-methodist-debakey-heart-vascular-center
Nasdaq